#5721 HEPATITIS B VIRUS REACTIVATION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH BELATACEPT

Abstract Background and Aims Hepatitis B virus (HBV) reactivation in kidney transplant recipients may be associated with liver failure graft loss, especially anti-HBc antibody (HBcAb)-positive HBs antigen (HBsAg)-negative patients. Belatacept, a selective costimulation blocker, has been used transplantation for some time of other viruses as BK or CMV. However, there are few data on HBV among treated belatacept. Method We performed retrospective study two French centres including all receiving Among HBcAb-positive patients, we analyzed rate, outcomes risks factors. Results 135 patients belatacept were included, 32 HBcAb-positive. Seven reactivated (21.9% patients), 5 HBsAg-negative (16.7%); occurred 54.8 (± 70.9) months after transplantation. There was no significant difference survival between that did not: 5-year patient 100% (28.6; 100) 83.4% (67.6; 100), respectively (p = 0.363) 79.8% (61.7; 0.335). No factor, HBsAb positivity antiviral prophylaxis, statistically the risk reactivation. Conclusion Compared to studies exist this area, rate high our study. Our findings suggest systematic prophylaxis should considered close monitoring serology viral load these detect early